Denemek ALTIN - Özgür
Swiggy delivers for Prosus with 23% IRR
Mint Kolkata
|June 24, 2025
Prosus saw its core headline earnings grow 47% on-year to $7.4 billion, up from $5 billion in the previous fiscal
Dutch investment group Prosus' internal rate of return (IRR) for Indian portfolio companies Swiggy and PayU India stood at 23% and 13%, in 2024-25.
Prosus' venture investments ElasticRun, Meesho, and PharmEasy had an IRR of 28%, 20%, and -29%, showed the firm's financial results for the fiscal year. In 2024, Swiggy saw its gross order value (GOV) grow by 29%, while its adjusted earnings before interest, taxes, depreciation, and amortization (Ebitda) losses fell to $182 million from $261 million a year ago.
Bu hikaye Mint Kolkata dergisinin June 24, 2025 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Mint Kolkata'den DAHA FAZLA HİKAYE
Mint Kolkata
With a $35 bn push, Amazon puts e-comm rivals on notice
Funds will support e-commerce, Amazon Web Services, Prime Video, MX Player and devices
2 mins
December 12, 2025
Mint Kolkata
US bombers join Japanese jets in show of force
The move follows Chinese and Russian drills in the skies and seas around Japan, South Korea
1 mins
December 12, 2025
Mint Kolkata
The kindness of strangers is one of the great rewards of running
How people often go out of their way to help is worth more than the health benefits that runners seek
3 mins
December 12, 2025
Mint Kolkata
Jeff Bezos and Elon Musk race to bring data centers to space
Space companies backed by tech billionaires hope to move AI data centers off Earth
3 mins
December 12, 2025
Mint Kolkata
Volltamp rally now hinges on growth beyond peak margins
Shares of Voltamp Transformers
1 mins
December 12, 2025
Mint Kolkata
Axis AMC to launch 3rd pvt credit fund
Fund house is looking to scale sharply in private-credit market
2 mins
December 12, 2025
Mint Kolkata
Novo moves Delhi HC on semaglutide
Danish drugmaker Novo Nordisk has moved Delhi high court's division bench seeking to restrain Dr. Reddy’s Laboratories from domestically manufacturing and exporting semaglutide—the blockbuster weight-loss and diabetes drug—to non-patent countries until its patent expires in March 2026.
1 min
December 12, 2025
Mint Kolkata
Bar on Prabhudas Lilladher stayed
The Securities Appellate Tribunal (SAT) has stayed an enquiry order issued by the Securities and Exchange Board of India (Sebi) that had barred Prabhudas Lilladher from taking on any new business for seven days over rule breaches.
1 min
December 12, 2025
Mint Kolkata
HOMEOWNERSHIP 101: KEY COSTS BEYOND EMIs EVERY BUYER SHOULD BUDGET FOR
Owning a house is a dream for many.
3 mins
December 12, 2025
Mint Kolkata
Don't judge OMCs by their value
Oil marketing companies are likely to post strong earnings in FY26, given softer crude and unchanged retail prices.
2 mins
December 12, 2025
Listen
Translate
Change font size